GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » COGS-to-Revenue

Rezolute (Rezolute) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute COGS-to-Revenue?

Rezolute's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Rezolute's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Rezolute's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Rezolute COGS-to-Revenue Historical Data

The historical data trend for Rezolute's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute COGS-to-Revenue Chart

Rezolute Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rezolute Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rezolute COGS-to-Revenue Calculation

Rezolute's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Rezolute's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rezolute  (NAS:RZLT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Rezolute's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Rezolute COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rezolute's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Rezolute (Rezolute) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » COGS-to-Revenue
Comparable Companies
RAIN COEP ICCC PRTG LPTX BOLT GDTC PASG ELDN CELU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Website
https://www.rezolutebio.com
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields officer: Chief Accounting Officer 890 SANTA CRUZ AVE., MENLO PARK CA 94025